RxDoctor Payments Data

Thomas Currey, OD

Optometrist · Germantown, TNNPI 1295738862

Payments from drug & device makers

$897in general payments, 2019–2025

Across 18 payments — averaging $49.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$255
  • Eyepoint US, Inc.$136
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$112
  • Aerie Pharmaceuticals, Inc.$97
  • Johnson & Johnson Vision Care, Inc.$96
  • Johnson & Johnson Surgical Vision, Inc.$76
  • plus $124 from 4 others

What the payments were for

  • Food & beverage$897100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$897 in reported general payments places this provider in the 55th percentile of 1,122 optometrist providers in Tennessee.

See all optometrist providers in Tennessee

Medicare billing

Part B allowed, 2024
$115,876
Medicare patients
515
Services billed
2,112

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost64$34,707
RestasisCyclosporine32$20,847
VyzultaLatanoprostene Bunod24$11,224
CombiganBrimonidine Tartrate/Timolol24$6,795
RhopressaNetarsudil Mesylate12$5,170
Brimonidine Tartrate159$2,863
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol24$2,739
Latanoprost187$2,654
Timolol Maleate73$763
Doxycycline Hyclate16$250
ErythromycinErythromycin Base11$140
Azithromycin14$66

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan$29$62,350120 claims
Bausch & Lomb Americas Inc.Vyzulta$65$11,22424 claims
Aerie Pharmaceuticals, Inc.Rhopressa$97$5,17012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,122 optometrist providers in Tennessee.

Other optometrist in Germantown

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →